Trial Profile

Evaluation of the Safety and Efficacy of Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms FavorAx

Most Recent Events

13 Feb 2021 Results (n=55) from expansion study cohort assessing long-term survival of favorable-risk patients presented at the 2021 Genitourinary Cancers Symposium
03 Jan 2019 Status changed from active, no longer recruiting to completed.
03 Jan 2019 Results assessing efficacy of Axitinib in metastatic renal cancer patients published in the Targeted Oncology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com